|
|
Volumn 14, Issue 6, 2015, Pages 369-371
|
|
Oncolytic viruses get a boost with first FDA-approval recommendation
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CG 0070;
CHIMERIC ANTIGEN RECEPTOR;
CVA 21;
DNX 2401;
ENADENOTUCIREV;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
H 101;
IPILIMUMAB;
LONTUCIREV;
ONCOLYTIC ADENOVIRUS;
ONCOLYTIC VIRUS;
ONCOS 102;
PELAREOREP;
PEMBROLIZUMAB;
PEXASTIMOGENE DEVACIREPVEC;
TALIMOGENE LAHERPAREPVEC;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC AGENT;
VIRUS VACCINE;
ADOPTIVE IMMUNOTHERAPY;
BLADDER CANCER;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
COLON CANCER;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESPONSE;
ENTEROVIRUS;
FOOD AND DRUG ADMINISTRATION;
GENETIC ENGINEERING;
GLIOBLASTOMA;
HEAD AND NECK CANCER;
HERPESVIRIDAE;
HUMAN;
LICENSING;
LIVER CANCER;
LUNG CANCER;
MELANOMA;
NEOPLASM;
NEUROBLASTOMA;
NONHUMAN;
ONCOLYTIC VIROTHERAPY;
PANCREAS CANCER;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SHORT SURVEY;
SOLID TUMOR;
TUMOR IMMUNITY;
ANIMAL;
GENETICS;
IMMUNOLOGY;
LEGISLATION AND JURISPRUDENCE;
NEOPLASMS;
UNITED STATES;
ANIMALS;
ANTINEOPLASTIC AGENTS;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
NEOPLASMS;
ONCOLYTIC VIRUSES;
UNITED STATES;
VIRAL VACCINES;
|
|
EID: 84930319339
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4643 Document Type: Short Survey |
|
Times cited : (27)
|
|
References (0)
|
